| Primary |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
14.3% |
| Immunodeficiency Common Variable |
13.7% |
| Hypogammaglobulinaemia |
8.3% |
| Myasthenia Gravis |
7.7% |
| Idiopathic Thrombocytopenic Purpura |
6.5% |
| Multiple Sclerosis |
6.0% |
| Guillain-barre Syndrome |
4.8% |
| Product Used For Unknown Indication |
4.8% |
| Encephalitis |
4.2% |
| Bone Marrow Transplant |
3.6% |
| Demyelinating Polyneuropathy |
3.6% |
| Infection |
3.0% |
| Secondary Immunodeficiency |
3.0% |
| Dermatomyositis |
2.4% |
| Diarrhoea |
2.4% |
| Drug Use For Unknown Indication |
2.4% |
| Immunodeficiency |
2.4% |
| Kidney Transplant Rejection |
2.4% |
| Neuropathy Peripheral |
2.4% |
| Selective Igg Subclass Deficiency |
2.4% |
|
| Vomiting |
10.7% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
9.7% |
| Cerebrovascular Accident |
8.7% |
| Myocardial Infarction |
6.8% |
| Pulmonary Embolism |
6.8% |
| Pyrexia |
5.8% |
| Rash |
5.8% |
| Product Quality Issue |
4.9% |
| Tachycardia |
4.9% |
| Tremor |
4.9% |
| Pseudomonas Infection |
3.9% |
| White Blood Cell Count Decreased |
3.9% |
| Acute Myocardial Infarction |
2.9% |
| Arteriovenous Fistula Thrombosis |
2.9% |
| Hepatitis B |
2.9% |
| Htlv-1 Test Positive |
2.9% |
| Infusion Related Reaction |
2.9% |
| Ischaemic Stroke |
2.9% |
| Product Substitution Issue |
2.9% |
| Splenic Infarction |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
16.3% |
| Drug Use For Unknown Indication |
13.0% |
| Primary Immunodeficiency Syndrome |
11.0% |
| Idiopathic Thrombocytopenic Purpura |
10.4% |
| Premedication |
7.9% |
| Immunodeficiency Common Variable |
5.7% |
| Demyelinating Polyneuropathy |
5.5% |
| Encephalitis |
5.3% |
| Immunodeficiency |
4.0% |
| Lewis-sumner Syndrome |
4.0% |
| Antiphospholipid Syndrome |
3.5% |
| Myasthenia Gravis |
2.6% |
| Anaemia |
2.0% |
| Renal Transplant |
1.5% |
| Hypogammaglobulinaemia |
1.3% |
| Multiple Sclerosis |
1.3% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
1.1% |
| Cytomegalovirus Infection |
1.1% |
| Hypertension |
1.1% |
| Immunoglobulin Therapy |
1.1% |
|
| Transmission Of An Infectious Agent Via A Medicinal Product |
25.0% |
| Anti-erythrocyte Antibody Positive |
8.3% |
| Drug Intolerance |
7.4% |
| Intra-uterine Death |
7.4% |
| Vomiting |
6.5% |
| Nail Disorder |
5.6% |
| Nausea |
4.6% |
| Deep Vein Thrombosis |
3.7% |
| Myocardial Infarction |
3.7% |
| Product Quality Issue |
3.7% |
| Prostatitis |
3.7% |
| Pseudomonas Infection |
3.7% |
| Rash |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Cerebrovascular Accident |
1.9% |
| Dermatitis Exfoliative |
1.9% |
| Hepatitis B |
1.9% |
| Meningitis |
1.9% |
| Myocardial Ischaemia |
1.9% |
| Respiratory Distress |
1.9% |
|
| Concomitant |
| Multiple Myeloma |
14.1% |
| Drug Use For Unknown Indication |
11.5% |
| Product Used For Unknown Indication |
10.9% |
| Chronic Lymphocytic Leukaemia |
9.0% |
| Non-hodgkin's Lymphoma |
5.8% |
| Antibiotic Therapy |
5.1% |
| Extranodal Marginal Zone B-cell Lymphoma (Malt Type) |
5.1% |
| Pain |
5.1% |
| Pyoderma Gangrenosum |
5.1% |
| Chronic Myeloid Leukaemia |
3.8% |
| Infection Prophylaxis |
3.8% |
| Diabetes Mellitus |
3.2% |
| Immunosuppression |
2.6% |
| Intestinal Transplant |
2.6% |
| Renal Failure Chronic |
2.6% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
1.9% |
| Hypogammaglobulinaemia |
1.9% |
| Pneumonia |
1.9% |
| Prophylaxis |
1.9% |
| Prophylaxis Against Transplant Rejection |
1.9% |
|
| Sepsis |
18.9% |
| Aplasia Pure Red Cell |
10.8% |
| Neoplasm Progression |
8.1% |
| Vomiting |
8.1% |
| Orbital Pseudotumour |
5.4% |
| Squamous Cell Carcinoma Of Skin |
5.4% |
| Toxic Epidermal Necrolysis |
5.4% |
| Tumour Haemorrhage |
5.4% |
| Dysphagia |
2.7% |
| Graft Versus Host Disease |
2.7% |
| Haematology Test Abnormal |
2.7% |
| Haemolysis |
2.7% |
| Leukopenia |
2.7% |
| Neutropenia |
2.7% |
| Progressive Multifocal Leukoencephalopathy |
2.7% |
| Respiratory Failure |
2.7% |
| Sensory Disturbance |
2.7% |
| Status Epilepticus |
2.7% |
| Steroid Withdrawal Syndrome |
2.7% |
| Systemic Inflammatory Response Syndrome |
2.7% |
|
